1608P The impact of COVID-19 on the delivery of systemic anti-cancer treatment at Guy’s Cancer Centre
Saoirse Dolly(Guy's and St Thomas' NHS Foundation Trust), M. Van Hemelrijick(King's College London), Charalampos Gousis(Guy's and St Thomas' NHS Foundation Trust), Vasiliki Michalarea(Royal Marsden Hospital), Jose Roca(Guy's and St Thomas' NHS Foundation Trust), James Spicer(King's College London), Ailsa Sita-Lumsden(Guy's and St Thomas' NHS Foundation Trust), Mary Lei(Guy's and St Thomas' NHS Foundation Trust), Debra H. Josephs(Guy's and St Thomas' NHS Foundation Trust), Lucy Flanders(Guy's and St Thomas' NHS Foundation Trust), Charlotte Moss(Southampton General Hospital), Elinor J. Sawyer(King's College London), Eirini Tsotra(Guy's and St Thomas' NHS Foundation Trust), Paul J. Ross(King's College Hospital NHS Foundation Trust), Beth Russell(King's College London), Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Muhammad Khan(Guy's and St Thomas' NHS Foundation Trust), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Daniel Smith(Guy's and St Thomas' NHS Foundation Trust), Kamarul Zaki(Guy's and St Thomas' NHS Foundation Trust), Deborah Enting(Guy's and St Thomas' NHS Foundation Trust)
Cited by 0
Related Papers
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
|The Lancet Oncology|2021|614
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
|The Lancet Oncology|2021|401